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ABSTRACT
Metastasis represents a key factor associated with poor prognosis of head 
and neck squamous cell carcinoma (HNSC). However, the underlying molecular 
mechanisms remain largely unknown. In this study, our liquid chromatography with 
tandem mass spectrometry analysis revealed a number of significantly differentially 
expressed membrane/membrane-associated proteins between high invasive UM1 
and low invasive UM2 cells. One of the identified membrane proteins, Syntenin-1, 
was remarkably up-regulated in HNSC tissues and cell lines when compared to the 
controls, and also over-expressed in recurrent HNSC and high invasive UM1 cells. 
Syntenin-1 over-expression was found to be significantly associated with lymph node 
metastasis and disease recurrence. HNSC patients with higher syntenin-1 expression 
had significantly poorer long term overall survival and similar results were found in 
many other types of cancers based on analysis of The Cancer Genome Atlas data. 
Finally, knockdown of syntenin-1 inhibited the proliferation, migration and invasion 
of HNSC cells, and opposite findings were observed when syntenin-1 was over-
expressed. Collectively, our studies indicate that syntenin-1 promotes invasion and 
progression of HNSC. It may serve as a valuable biomarker for lymph node metastasis 
or a potential target for therapeutic intervention in HNSC.
INTRODUCTION
Head and neck squamous cell carcinoma (HNSC) 
is the sixth most common type of cancer, accounting for 
approximately 2–3% of all malignancy worldwide [1, 2]. 
Despite the advances in surgery and radiochemotherapy 
for the disease treatment, the five-year survival rate of 
HNSC remains stagnant at about 50% in the past few 
decades [3, 4]. Metastasis has been demonstrated to be 
a key prognostic factor responsible for the poor clinical 
outcome of HNSC [5, 6]. Lymphatic spread is the 
major pathway for the dissemination of HNSC [7], and 
lung, liver and bone are the usual organs suffered from 
distant metastasis due to the hematogenous spread [8]. 
Understanding the molecular mechanisms that activate the 
metastasis process is an important strategy to improve the 
prognosis of HNSC. 
Metastasis cascade represents a multi-step process, 
which includes physical detachment of cancer cells from 
the parental tumor, intravasation into blood or lymphatic 
vessels, survival in the circulation, extravasation, and 
subsequent proliferation in competent organs [9–11]. 
Membrane proteins especially cell surface molecules 
are essential for the metastasis process [12, 13]. 
Proteomics-based approach is an effective strategy for 
identification of novel metastasis-associated target proteins. 
We previously showed that the membrane proteomes 
were remarkably different between pancreatic ductal 
adenocarcinoma cells of primary and metastatic origin. 
Many of the identified proteins were regulators of cell-to-
cell adhesion and tumor cell invasion [14]. Leth-Larsen 
et al. compared the membrane proteomes between high 
and low invasive breast cancer cell lines and identified 
13 significantly deregulated membrane proteins. High 
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expression of two identified molecules, ecto-5′-nucleotidase 
and integrin β1, in clinical samples were found to be closely 
correlated with poor clinical outcome which were measured 
as tumor spread or distant recurrence [15].
In this study, we first compared the membrane 
proteomes between high invasive UM1 and low invasive 
UM2 cells. A number of differentially expressed 
membrane and membrane-associated proteins, including 
syntenin-1 encoded by syndecan binding protein (SDCBP) 
gene, were identified. We then determined the role of 
syntenin-1 and its clinical significance in HNSC.
RESULTS
Differentially expressed membrane or 
membrane-associated proteins between UM1 
and UM2 cells
In total, 598 and 660 membrane/membrane-
associated proteins were identified from UM1 and UM2 
cells, respectively, based on the liquid chromatography 
with tandem mass spectrometry (LC-MS/MS) analysis 
and database searching. Three hundred and ninety-three 
proteins were present in both cell lines but others were 
only found in either UM1 (n = 205) or in UM2 (n = 267) 
cells (Figure 1A). All the identified proteins and their 
relative information (access number, molecular weight, 
isoelectric point, number of unique peptides and number of 
total peptides) from the two cell lines were summarized in 
Supplementary Tables S1–S3. The subcellular localization 
of the membrane /membrane-associated proteins in UM1 
and UM2 cells was shown in Figure 1B.
Representative membrane/membrane-associated 
proteins only found in UM1 or UM2 cells or in both 
cell lines were summarized in Tables 1–3, respectively. 
Membrane/membrane-associated proteins with metastasis-
promoting function were prone to be found or had a higher 
expression level in UM1 cells versus UM2 cells. However, 
those proteins associated with adhesion property were 
more likely to be detected in UM2 cells.
SDCBP is upregulated in HNSC and associated 
with poor prognosis
The expression level of SDCBP was significantly 
increased in HNSC tissues compared to the adjacent 
normal tissues (P < 0.0001, Figure 2A) and closely 
associated with lymph node metastasis (P = 0.0254) 
(Table 4). In addition, the HNSC patients in the high 
SDCBP expression group had remarkably shorter long-
term overall survival (P = 0.0028, Figure 2B). Moreover, 
the cancer patients with higher expression of SDCBP 
had poorer long-term overall survival rates in many 
other types of cancers including breast cancer (BRCA, 
P = 0.0083), glioblastoma (GBM, P = 0.0214), kidney 
renal papillary cell carcinoma (KIRP, P = 0.0104), low 
grade glioma (LGG, P < 0.0001), lung adenocarcinoma 
(LUAD, P = 0.0085), lung squamous cell carcinoma 
(LUSC, P = 0.0004), sarcoma (SARC, P = 0.0223), 
prostate adenocarcinoma (PAAD, P = 0.0130), thyroid 
carcinoma (THCA, P = 0.0021) and uveal melanoma 
(UVM, P = 0.0003) (Figure 3).
Syntenin-1 is over-expressed in HNSC cell lines 
and tissues
Real-time PCR and Western blotting both showed 
that syntenin-1 was significantly over-expressed in both 
UM1 and UM2 cells when compared to NHOKs (P < 0.01) 
(Figure 4A). In addition, syntenin-1 was significantly 
upregulated in high invasive UM1 cells versus low 
invasive UM2 cells (P < 0.01) (Figure 4B). 
The expression level of syntenin-1 was significantly 
upregulated in HNSC compared to adjacent normal 
tissues (P < 0.01) (Figure 4C). For the IHC analysis, the 
positive staining of cells was identified as bright yellow, 
yellow or brown-yellow granules. As shown in Figure 5, 
syntenin-1 was upregulated in HNSC but barely detected 
in normal tissues. In addition, the staining intensity of 
syntenin-1 was higher in recurrent HNSCs (Figure 5), and 
HNSC patients with higher IHC scores were significantly 
associated with lymph node metastasis (P = 0.0006) and 
disease recurrence (P = 0.0182) (Table 5). 
Down-regulation of syntenin-1 inhibits the 
proliferation, migration and invasion capacity of 
HNSC cells
Western blot analysis showed that the expression 
level of syntenin-1 was significantly suppressed in 
the UM1 cells transfected with syntenin-1 siRNA 
(sisyntenin-1) when compared to those transfected with 
scrambled siCTRL (Figure 6A). Cell proliferation was 
determined by an MTT assay in UM1 cells at 24 h, 
48 h, and 72 h after siRNA transfection. UM1 cells 
with sisyntenin-1 transfection experienced a significant 
reduction in cell numbers when compared to the controls 
after 48 h and 72 h (P < 0.01) (Figure 6B). Meanwhile, 
UM1 cells with sisyntenin-1 transfection had suppressed 
growth capacity as indicated by the colony formation 
assay, with significantly fewer colonies formed than the 
cells transfected with siCTRL (Figure 6C). In addition, the 
percentage of EdU positive cells was lower in the cells 
with sisyntenin-1 transfection when compared to those 
with siCTRL transfection (P < 0.01) (Figure 6D).
Wound healing assay was performed to evaluate the 
effect of syntenin-1 inhibition on cell migration at 16 h 
after the cells reaching confluence. As shown in Figure 6E, 
in relative to siCTRL-transfected cells, the migration 
capability of cells transfected with sisyntenin-1 was 
significantly reduced. The wound gap between cell layers 
was significantly greater for the UM1 cells transfected 
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with sisyntenin-1 when compared to those transfected with 
siCTRL (P < 0.01) (Figure 6E). 
Matrigel invasion assay was used to measure the 
number of invaded UM1 cells after sisyntenin-1 or siCTRL 
transfection. The results showed that the cells transfected 
with sisyntenin-1 had a significant reduction in the number 
of cells crossing the transwell membrane when compared 
to those transfected with siCTRL (P < 0.01) (Figure 6F). 
Up-regulation of syntenin-1 promotes the 
proliferation, migration and invasion capacity 
of HNSC cells
UM1 cells were successfully infected with lentiviral 
particles and the expression level of syntenin-1 protein 
was remarkably increased after lenti-syntenin-1 infection 
(Figure 7A). Similarly, the cell proliferation was assessed 
with the MTT, cell colony formation and EdU assays. 
The results indicated that the cells with syntenin-1 
overexpression had higher OD values at 48 h (P < 0.05) 
and 72 h (P < 0.01) and stronger colony forming ability. 
In addition, syntenin-1 overexpression led to a higher 
percentage of EdU positive cells (P < 0.01) (Figure 7A–7D).
As shown in Figure 7E, our results indicated that 
UM1 cells with syntenin-1 overexpression were more 
proficient than empty vector-transduced cells at closing 
the artificial wound (P < 0.01). Syntenin-1 upregulation 
also significantly enhanced the invasive capacity of UM1 
cells (P < 0.01).
DISCUSSION
HNSC remains to be a significant public health 
problem and thus exploring the molecular mechanisms 
accounting for the development and progression of this 
malignancy is extremely crucial [16, 17]. In this study, we 
used an LC/MS-based approach to compare the membrane 
proteomes between highly and low invasive cancer 
cells and revealed a number of differentially expressed 
membrane/membrane-associated proteins. It should be 
noted that, although some proteins were only detected in 
UM1 cells, they may not be completely absent in UM2 
cells, and vice versa. This is partially due to sensitivity 
limitation of LC-MS for analysis and identification of 
low abundant proteins and many membrane proteins are 
known to be expressed in low copy numbers [12, 14]. 
For the membrane/membrane-associated proteins only 
detected in UM1 cancer cells, many of them have a strong 
correlation with cancer invasion or metastasis. For instance, 
stress-induced-phosphoprotein 1 (STIP-1) is an adaptor 
protein that coordinates the functions of HSP70 and HSP90 
in protein folding. Downregulation of STIP-1inhibited the 
migration and invasion capability of ovarian cancer cells 
[18]. Calcium-activated potassium channel subunit alpha-1 
(KCNMA1) was overexpressed in malignant pleural 
mesothelioma (MPM), and KCNMA1 downregulation 
suppressed the migration of MPM cells [19]. On the other 
hand, many of the membrane or membrane associated 
proteins only found in UM2 cells have a functional role in 
Figure 1: LC-MS/MS analysis and identification of membrane/membrane-associated proteins in UM1 and UM2 cells. 
(A) The commonly and differentially expressed proteins between UM1 and UM2 cells; (B) Subcellular localization of the identified 
membrane and membrane-associated proteins in UM1 and UM2 cells.
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Table 1: The representative membrane or membrane-associated proteins only identified in UM1 cells
Accession # Protein name Molecular  
weight (KDa)
PI Number of unique 
peptides
Number of total 
peptides
P09525 Annexin A4 35.75 5.84 2 2
Q12791 Calcium-activated 
potassium channel 
subunit alpha-1
137.56 6.66 2 2
Q9H4A6 Golgi 
phosphoprotein 3
33.81 6.05 3 3
P04629 High affinity nerve 
growth factor 
receptor
84.17 5.99 2 2
P05362 Intercellular 
adhesion molecule 
1
55.22 8.15 3 3
P18669 Phosphoglycerate 
mutase 1
28.67 6.75 4 7
P31948 Stress-induced-
phosphoprotein 1
62.64 6.40 2 2
O00560 Syntenin-1 32.31 7.04 2 3
cell-cell adhesion (e.g., desmoplakin, junction plakoglobin 
and stomatin-like protein 2), which connect the neighboring 
cells together and might accounting for the low metastatic 
capacity of UM2 cells. As for the differentially expressed 
proteins that were identified in both UM1 and UM2 cells, 
UM1 cells exhibited an over-expression of metastasis-
related proteins but with under-expression of adhesion-
related molecules in comparison to UM2 cells. For instance, 
the expression level of Reticulon-4 protein was about 
6 times higher in UM1 cells than UM2 cells. In fact, previous 
study has shown that Reticulon-4 was overexpressed in 
human breast invasive ductal carcinoma and activated the 
epithelial-mesenchymal transition, indicating Reticulon-4 
might be a metastasis-promoting molecule [20]. To the best 
of our knowledge, many of metastasis-associated proteins 
listed in Tables 1–3 were identified in HNSC for the first 
time. Further studies are warranted to investigate their role 
in the carcinogenesis of HNSC.
Our studies showed that syntenin-1 was 
overexpressed in HNSC cell lines as well as tissue samples. 
In addition, upregulation of syntenin-1 was associated with 
lymph node metastasis and disease recurrence. HNSC 
patients with higher syntenin-1 expression suffered poorer 
long-term overall survival. Moreover, syntenin-1 inhibition 
suppressed the proliferation, migration and invasion 
capacity of HNSC cells in vitro, and vice versa. These data 
demonstrated that syntenin-1 may function as an oncogenic 
molecule in HNSC and might serve as a potential target 
for therapeutic intervention. Syntenin-1, also known as 
melanoma differentiation associated gene-9 (mda-9), is 
a PDZ domain-containing adapter protein involving in 
various biological processes such as membrane trafficking, 
receptor clustering, cell adhesion, synaptic transmission, 
SOX4 activation, and exosome biogenesis [21]. Syntenin-1 
deregulation has been reported in multiple primary cancers 
and its activity appears to be a driver of cancer progression. 
A number of signaling pathways including, but not limited 
to FAK, c-Src, p38-MAPK, AKT, NFkB, IGFBP2, EGFR, 
SPRR1B, and VEGFR may be mediated by syntenin-1 
to promote tumorigenesis [22]. The role of syntenin-1 in 
cancer is most well studied in melanoma. The expression 
level of syntenin-1 was found to be overexpressed in human 
melanoma cell lines and patient derived tumor samples and 
associated with advanced stages of melanoma. Moreover, 
ectopic expression of syntenin-1 promoted the oncogenic 
activities of melanoma cells both in vitro and in vivo, and 
vice versa [23]. Das et al. showed that syntenin-1 induced 
the angiogenesis in melanoma by activating the expression 
of several angiogenesis-promoting factors including Src, 
FAK, AKT, HIF-1α and IGFBP-2, indicating syntenin-1 
promoted the progression of melanoma [24]. Lastly but not 
the least, syntenin-1 was overexpressed in high metastatic 
breast cancer cell lines and tissues, and was significantly 
associated with the progression of breast cancer [25]. 
MATERIALS AND METHODS
Tissue samples and IHC analysis
Seventy-four formalin-fixed paraffin-embedded 
(FFPE) tissue specimens and the clinical information 
were obtained from the Department of Dentistry, 
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Table 2: The representative membrane/membrane-associated proteins only identified in UM2 cells
Accession # Protein name Molecular  
weight (KDa)
PI Number of unique 
peptides
Number of total 
peptides
Q13740 CD166 antigen 62.26 5.71 6 11
6Q9UMD9 Collagen alpha-1(XVII) chain 150.42 8.89 4 4
P12111 Collagen alpha-3(VI) chain 340.81 6.15 2 2
P15924 Desmoplakin 331.77 6.44 4 5
P26006 Integrin alpha-3 113.51 6.13 2 3
P14923 Junction plakoglobin 81.74 5.75 4 6
O60716 Catenin delta-1 108.17 5.86 2 5
Q9UJZ1 Stomatin-like protein 2 35.69 5.37 6 38
Zhongnan Hospital, Wuhan University. This study was 
approved by the Institutional Research Ethics Committee 
at the Zhongnan Hospital, Wuhan University and the 
University of California, Los Angeles. Informed consent 
was obtained from all of patients or their relatives for 
the use of the tissues. For IHC analysis, FFPE tissue 
sections were deparaffinized by sequential washing 
with xylene, 100% ethanol, 95% ethanol, 80% ethanol 
and PBS. The endogenous peroxidase activity was 
quenched in methanol with 0.3% H2O2 for 5 min. The 
slides were blocked in PBS with 5% BSA for 30 min and 
then incubated overnight at 4 °C with mouse antibody 
against human Syntenin-1 at a dilution of 1:100 (Santa 
Cruz Biotech, Santa Cruz, CA, USA). After rinsing 
in PBS, the sections were incubated with horseradish 
peroxidase (HRP)-conjugated sheep anti-mouse IgG 
(1:2000; GE Healthcare, Piscataway, NJ, USA) for 2 h 
at room temperature. 
For the quantitative IHC analysis, the total staining 
score of syntenin-1 equals to the staining intensity (on a 
scale of 0–3: negative = 0, weak = 1, moderate = 2, and 
strong = 3) × the percentage of cells stained (on a scale of 
0–3: 0 = zero, 1 = 1–25%, 2 = 26–50%, and 3 = 51–100%), 
resulting in a score range of 0–9. The evaluation was 
performed by two independent investigators.
Analysis of SDCBP gene expression in tumor 
samples and its clinical significance
The clinical information and RNASeq V2 datasets 
of cancer patients were obtained from The Cancer Genome 
Atlas (TCGA) database (https://tcga-data.nci.nih.gov/tcga) 
to determine the clinical significance of syntennin-1 in 
cancers. Briefly the mRNA expression levels were log2-
transformed and X tile software was used to find out the 
best cutoff point to divide the cancer patients into high/low 
SDCBP expression groups. Kaplan–Meier overall survival 
curves were generated for patients whose follow-up data 
were available. The log-rank test was used to analyze 
survival differences between the two groups. 
Table 3: The representative membrane/membrane-associated proteins identified both in UM1 
and UM2 cells
Accession # Protein name Molecular weight 
(KDa)
PI Number of unique 
peptides (UM1/UM2)
Number of total 
peptides (UM1/UM2)
P07355 Annexin A2 38.47 7.56 25/24 330/227
P21964 Catechol 
O-methyltransferase
30.04 5.26 8/5 14/8
P23528 Cofilin-1 18.37 8.26 10/10 159/74
P15311 Ezrin 69.28 5.95 8/4 16/8
P09429 High mobility group 
protein B1
24.76 5.60 5/2 10/2
P17301 Integrin alpha-2 126.38 5.15 2/4 4/8
P05556 Integrin beta-1 86.19 5.27 4/8 14/22
Q9NQC3 Reticulon-4 129.93 4.42 8/8 183/29
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Figure 2: The expression level and clinical significance of SDCBP in HNSC. (A) SDCBP was significantly up-regulated in 
HNSC tissues compared to the controls (P < 0.0001); (B) The HNSC patients in the high SDCBP expression group suffered poorer long 
term overall survival than those in the low SDCBP expression group (P = 0.0028).
Cell culture
UM1 and UM2 oral cancer cell lines were cultured 
in the Dulbecco’s modified eagle medium (DMEM) 
supplemented with 10% fetal bovine serum, penicillin 
(100 U/mL), and streptomycin (100 μg/mL). Normal 
human oral keratinocytes (NHOKs) were cultured in 
EpiLife media supplemented with the human keratinocyte 
growth supplement (Invitrogen, Carlsbad, CA, USA). The 
cells were maintained at 37°C, 5% CO2 in a humidified 
cell culture incubator and passaged when they reached 
90–95% confluence.
Sample preparation
The ProteoExtract Native Membrane Protein 
Extraction Kit (EMD Chemicals, Gibbstown, NJ) was 
used to isolate the membrane proteins from the UM 1 
and UM 2 cells. Briefly, the cell pellet was washed three 
times in wash buffer, and then incubated with ice-cold 
Extract Buffer I under gentle agitation at 4°C for 10 min. 
Followed by centrifugation at 16,000g for 15 min at 4°C, 
the supernatant was discarded and 1 mL ice-cold Extract 
Buffer II was added to the pellet. This membrane protein 
extraction step was allowed for 30 min at 4°C under 
gentle agitation. Then the supernatant was collected after 
centrifugation at 16,000 g for 15 min 4°C.
SDS-PAGE and proteolytic cleavage
2-D Quant Kit (GE Healthcare, Piscataway, NJ) 
was used to determine the total membrane protein 
concentration. From each cell line 20 μg of membrane 
protein was loaded into a 4–12% NuPAGE Bis-Tris gel 
(Invitrogen, Carlsbad, CA) for SDS-PAGE separation. 
The gel was stained with the Simply Blue staining solution 
(Invitrogen) to visualize the proteins. Each gel was then 
cut into 15 sections evenly and enzyme-grade trypsin 
(Promega, Madison, WI) was used to cleave the proteins 
into peptides in each section.
Tandem MS and database searching
Liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) analysis of peptides was performed using 
a NanoLC system (Eksigent Technologies, Dublin, CA) 
and a LTQ mass spectrometer (Thermo Fisher, Waltham, 
MA). Using an autosampler, 5 μL aliquots of the peptide 
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Table 4: The association between SDCBP expression level and clinicopathological parameters 
of HNSC
Clinicopathological features
SDCBP expression
P
Low High
Age 60.82 ± 11.84 61.22 ± 12.38 0.7937
Gender
Female 111 27 0.0374
Male 334 47
T stage 0.2549
T1-T2 164 22
T3-T4 268 49
Lymph node metastasis 0.0254
No 217 26
Yes 209 45
Distant metastasis 0.8478
M0 420 68
M1 5 1
Stage 0.1649
I-II 106 12
III-IV 328 59
Angiolymphatic invasion 0.0917
No 196 26
Yes 103 23
Extracapsular spread 0.1330
No 216 30
Yes 90 20
Surgery margin status 0.6062
Negative 297 51
Positive 51 10
Close 40 10
HPV 16 status 0.2219
Negative 55 15
Positive 36 5
digest derived from each gel slice were injected for 
analysis. Followed by concentrating and desalting on a 
C18 IntegraFrit Nano-Precolumn (New Objective, Woburn, 
MA), the peptides were separated using a C18 reversed-
phase capillary column (New Objective). LC separation 
was performed at 400 nL/min with the following mobile 
phases: A, 5% acetonitrile/0.1%formic acid (v/v); B, 95% 
acetonitrile/0.1% formic acid (v/v). The chosen LC gradient 
was: from 5% to 15% B in 1 min, from 15% to 100% B in 
40 min, and then maintained at 100%B for 15 min.
Database searches were performed using the X! 
Tandem search engine against the SwissProt protein 
sequence database. The search criteria were set with 
a mass accuracy of 0.4 Da and semi-style cleavage by 
trypsin. Positive identification of proteins was based on 
two or more unique peptides. The total number of peptides 
was used to estimate the abundance of a protein.
siRNA knockdown of syntenin-1
UM1 cells were transfected with double-stranded 
siRNA using the RNAiMAX transfection regent 
(Invitrogen) according to the manufacturer’s instruction. 
Validated siRNAs of syntenin-1 (sisyntenin-1, sc-42164) or 
scrambled control siRNAs (siCTRL, Santa Cruz Biotech) 
were mixed with the transfection reagent respectively and 
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Figure 3: Higher SDCBP expression was associated with poorer overall survival in other types of cancers. The cancer patients 
with higher SDCBP expression suffered remarkably shorter overall survival in a number of other cancers including BRCA (P = 0.0083), GBM 
(P = 0.0214), KIRP (P = 0.0104), LGG (P < 0.0001), LUAD (P = 0.0085), LUSC (P = 0.0004), SARC (P = 0.0223), PAAD (P = 0.0130), THCA 
(P = 0.0021) and UVM (P = 0.0003).
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Figure 4: Syntenin-1 was overexpressed in HNSC cell lines and tissues. (A–B) Syntenin-1 mRNA and protein levels were 
overexpressed significantly in both UM1 and UM2 cells compared to NHOKs (**P < 0.01). In addition, the expression level of syntenin-1 
was significantly over-expressed in high invasive UM1 cells compared to low invasive UM2 cells (**P < 0.01). (C) The expression level of 
syntenin-1 was significantly overexpressed in HNSC tissues in comparison with the adjacent normal tissues (**P < 0.01).
Figure 5: IHC analysis of syntenin-1 in HNSC. Syntenin-1 was upregulated in HNSC while barely detected in normal tissues. The 
staining intensity of syntenin-1 was also higher in recurrent HNSC compared with non-recurrent HNSC.
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then added to the cell culture. After overnight incubation, the 
siRNAs were removed and the cells were further cultured in 
fresh media for 48 h before any additional experiments. 
Production of syntenin-1 recombinant lentiviral 
vectors
We cloned syntenin-1 into the pGCL-GFP 
vector and constructs were confirmed by sequencing. 
Recombinant lentiviral vectors and packaging vectors 
were then transfected into 293T cells. The supernatant 
liquor containing lentiviruses was harvested 72 hours 
after transfection. The lentiviruses were then purified 
by ultracentrifugation, and the titer of lentiviruses 
was determined. The empty vector was packaged as a 
negative control. The cancer cells were infected with the 
lentiviruses at a multiplicity of infection of 25.
Real-time PCR
Total RNA was isolated from cancer cells using 
TRIzol (Takara, Dalian, China) according to the 
manufacturer’s instructions. First-strand complementary 
DNA synthesis was performed using the SuperScript III 
Reverse Transcriptase (Invitrogen). The complementary 
DNA levels were amplified with Light Cycler 480â SYBR 
Green I MasterMix (Roche, Applied Science, Indianapolis, 
IN, USA) using the CFX96 Real-Time PCR detection 
system (Bio-Rad Laboratories Inc., Hercules, CA, USA). 
Gene expression was normalized against glyceraldehyde 
3-phosphate dehydrogenase (GAPDH), and triplicate 
reactions were performed in three separate experiments.
Western blotting
The protein samples were loaded and separated 
on a 4–12% Bis-Tris NuPAGE gel (Invitrogen) and 
transferred onto a nitrocellulose membrane using a 
Trans-blot SD semi-dry transfer cell (Bio-Rad). The 
membranes were blocked for 2 h at room temperature 
in TBST buffer containing 5% nonfat milk (Santa Cruz 
Biotech), and incubated with mouse antibody against 
human Syntenin-1 (1:500; Santa Cruz Biotech) overnight, 
followed by HRP-linked sheep anti-mouse IgG (1:5000; 
GE Healthcare). Signal detection was performed with the 
ECL-Plus Western blotting reagent kit (GE Healthcare).
Table 5: The association between syntenin-1 immunostaining and clinicopathological parameters 
of HNSC
Clinicopathological feature Number Staining score P
Age 0.6369
<60 58 5.41 ± 2.11
≥60 16 5.68 ± 1.72
Gender 0.8422
Female 27 5.41 ± 1.99
Male 47 5.51 ± 2.06
T stage 0.2537
T1-T2 51 5.29 ± 2.05
T3-T4 23 5.87 ± 1.95
Lymph node metastasis 0.0006
No 39 4.73 ± 1.99
Yes 35 6.30 ± 1.73
Recurrence 0.0182
No 54 5.14 ± 2.05
Yes 20 6.38 ± 1.67
Stage 0.0670
I-II 25 4.87 ± 1.67 
III-IV 49 5.78 ± 2.14
Differentiation 0.1383
Well 35 4.99 ± 2.16
Moderate 23 5.76 ± 1.80
Poor 16 6.10 ± 1.87
Oncotarget82644www.impactjournals.com/oncotarget
Figure 6: Inhibition of syntenin-1 suppressed the proliferation, migration and invasion capacity of UM1 cells. 
(A) Syntenin-1 was significantly inhibited following sisyntenin-1 transfection. (B) The OD values were lower in syntenin-1 knockdown 
cells compared to the controls (**P < 0.01). (C) The number of colonies was significantly lower for syntenin-1 knockdown cells versus the 
controls. (D) The percentage of EdU-positive cells was lower for syntenin-1 knockdown cells (**P < 0.01). (E) The migration capability 
of syntenin-1 knockdown cells was significantly inhibited (**P < 0.01). (F) The number of cancer cells that invaded through the membrane 
was remarkably reduced following syntenin-1 knockdown (**P < 0.01).
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Figure 7: Syntenin-1 overexpression promoted the proliferation, migration and invasion capacity of UM1 cells. 
(A) Syntenin-1 was significantly overexpressed following lenti-syntenin-1 infection. (B) The OD values were higher for syntenin-1 
overexpressed cells when compared to the controls (*P < 0.05, **P < 0.01). (C) The number of colonies was significantly higher for 
syntenin-1 overexpressed cells versus the controls. (D) The percentage of EdU positive cells was higher for lenti-syntenin-1 treated cells 
(**P < 0.01). (E) The UM1 cells with syntenin-1 overexpression were more proficient than empty vector-transduced cells at closing an 
artificial wound (**P < 0.01). (F) The number of cancer cells that invaded through the membrane was remarkably increased following 
sisyntenin-1 up-regulation (**P < 0.01).
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MTT assay
After 24 h of serum starvation, the cells were seeded 
into a 96-well plate at a density of 4000 cells/well. At the 
indicated time points, 20μL of MTT (Sigma-Aldrich, 
St. Louis, MO, USA) dissolved in PBS at 5 mg/ml was 
added to each culture well. Following by incubation for 
4 h at 37 °C, the supernatant was then discarded and the 
precipitate dissolved in 200 μl of dimethyl sulfoxide 
(DMSO, Sigma). The absorbance of each well was 
measured using a Synergy HT microplate reader (BioTek 
Instruments, Winooski, VT, USA) at 490 nm.
5-ethynyl-2′-deoxyuridine assay
The 5-ethynyl-2′-deoxyuridine (EdU) detection 
kit (Invitrogen) was used to evaluate cell proliferation. 
According to the manufacturer’s instructions, the cells 
were treated with 10 μmol/L EdU for 4 h at 37°C and 
fixed with 3.7% formaldehyde for 15 min. After cells 
were washed with 3% BSA in PBS, they were treated 
with 0.5% Triton X-100 (Sigma-Aldrich) for 20 min and 
stained with 1 × Click-iT reaction cocktail for 30 minutes 
at room temperature. After PBS wash, Hoechst 33342 dye 
was used to stain the cell nucleus at room temperature 
for 30 min. Images were captured under a confocal laser 
scanning microscope (Olympus, Center Valley, PA). The 
assay was repeated in triplicate.
Cell colony formation assay
The cells were seeded into a 6-well plate at a density 
of 1000 cells/well in 2 mL medium. After incubation at 
37°C for 14 days, the cells were washed three times with 
PBS and stained with 0.5% crystal violet for 30 min.
Wound healing assay
The migratory ability of cancer cells was assessed 
with a wound healing assay. Briefly, 5 × 105 cells were 
seeded into a 6-well plate and grown until confluent. 
Subsequently, vertical scratch wounds were prepared 
using micropipette tips. For quantification, four random 
images per well were photographed at the beginning and 
after 8 h or 16 h, and the distance between the edges of the 
wound were calculated and analyzed by the NIH Image 
J software. 
Transwell Matrigel invasion assay
The invasion assays were performed with the 
Transwell Matrigel Invasion Chambers (BD Biosciences. 
Bedford, MA, USA). Following 24 h serum starvation, 
trypsinized cells (5 × 104 cells /well) were resuspended in 
DMEM containing 0.1% FBS and added to upper chamber 
of transwell inserts. DMEM supplemented with 10% FBS 
was used in the lower chamber to act as a chemoattractant. 
After 24 h, cells that had migrated through the membrane 
were fixed and stained with the HEMA 3 staining kit 
(Fisher Scientific, Pittsburgh, PA, USA). The invaded cells 
in four random fields were counted and expressed as the 
average number of cells per field under light microscopy 
(Eclipse TE2000, Nikon, Tokyo, Japan). 
Statistical analysis
The data were expressed as the mean ± standard 
deviation, and analyzed by the independent samples 
t-test and one-way ANOVA using the MedCalc (MedCalc 
Software Inc, Ostend, Belgium). The optimum cutoff point 
of mRNA expression in the TCGA patient cohort was 
calculated using X-tile software. Briefly, the expression 
data of SDCBP in cancer patients and the related patient 
survival information, including survival time and status 
(alive or dead), were loaded into X-tile. The cancer 
patients were then categorized into two groups (high and 
low SDCBP expression group) by running the “Kaplan–
Meier” program. Chi-square test was used to find out the 
association between the SDCBP mRNA expression level 
and clinicopathological parameter of HNSCs. Kaplan–
Meier method in combination with log-rank test was 
performed for the survival analysis, and P values < 0.05 
was considered to be statistically significant.
CONCLUSIONS
Our study has revealed a number of novel 
target membrane proteins that are warranted for 
further investigation of their role in HNSC invasion 
and metastasis. One of the identified target proteins, 
syntenin-1, was found to be overexpressed in HNSC 
cancer cells and tissues and significantly associated with 
poor prognosis and lymph node metastasis of HNSC. 
We also found that down-regulation/up-regulation of 
syntenin-1 inhibited/promoted the proliferation, migration 
and invasion of HNSC cells. Collectively, all these 
findings indicate that syntenin-1 is a promoter of HNSC 
invasion and metastasis and may serve as a prognostic 
biomarker of HNSC.
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